A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of kidney graft function in deceased-donor transplant recipients, with an additional 9-month follow-up.

You likely can't join if

• Organs: The presence of any of the following will exclude a kidney from being used in the study: 1) Kidney judged by the transplantation surgeon on call as not appropriate for transplantation. 2) Kidney allograft that was on HMP > 6 hrs prior to administration of IMP, or prior to transplantation for the control kidney. 3) Kidney judged to need preservation by HMP up until transplantation.
• Patients: The presence of any of the following will exclude a patient from participating in the study: 4) Increased risk of thrombosis (e.g., homozygous activated protein C [APC]-resistance) or bleeding (INR>1.5). 5) History of heparin-induced thrombocytopenia (HIT). 6) Known fish allergy. 7) History of or positive for human immunodeficiency virus (HIV). 8) Acute infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). 9) History of oncological malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin. 10) Previous kidney transplantation. 11) Scheduled to undergo multi-organ transplantation or dual kidney transplantation. 12) Positive T or B cell crossmatch by NIH anti-globulin lymphocytotoxicity method or positive T or B cell flow cytometry crossmatch AND donor specific anti-HLA antibody (DSA) detected by flow cytometry/Luminex based, antigen specific anti-HLA antibody testing, according to local practise. 13) Current drug and/or alcohol abuse. 14) History or presence of a medical condition or disease or psychiatric condition that in the investigator's assessment would place the patient at an unacceptable risk for study participation. 15) Lactating or pregnant women or women who intend to become pregnant. 16) Presence of ECG-based evidence of acute myocardial infarction, unstable angina, decompensated heart failure, third degree of heart block or cardiac arrhythmia associated with haemodynamic stability. 17) Any medical condition which in the opinion of the investigator makes the patient unsuitable for inclusion. 18) Enrolment in another concurrent clinical interventional study, or intake of an IMP, within 3 months prior to inclusion in this study. 19) Foreseeable inability to cooperate with given instructions or study procedures. 20) Patients receiving prophylactic treatment of lymphocyte-depleting agents (e.g., anti-thymocyte globulin [ATG] or Campath). 21) Hypersensitivity to the IMP or to any of the excipients, or previous hypersensitivity to heparin as well as any contraindication for heparin.* *Note: Contraindication includes (but not limited to – depending on the investigator’s decision): - Current or history of allergic thrombocytopenia to heparin (heparin-associated thrombocytopenia type II) - Active major bleeding and risk factors for major bleeding - Septic endocarditis - Spinal anesthesia, epidural anesthesia, lumbar puncture - Diseases where there is a suspicion of a lesion of the vascular system, e.g. Gastric and/or intestinal ulcers, consistent hypertension (greater than 110 mmHg diastolic), cerebral hemorrhage, trauma or central nervous system surgery, eye surgery, retinopathy, vitreous hemorrhage, cerebral artery aneurysm.